Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 23;23(1):62.
doi: 10.1186/s12943-024-01963-7.

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Kaifeng Liu #  1   2 , Meijia Li #  2 , Yudong Li #  2 , Yutong Li  2 , Zixin Chen  2 , Yiqi Tang  2 , Meitian Yang  2 , Guoquan Deng  2 , Hongwei Liu  3   4
Affiliations
Review

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Kaifeng Liu et al. Mol Cancer. .

Abstract

While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.

Keywords: Antibody‒drug conjugates; Cancer therapy; Clinical efficacy; FDA‒approved; Targeted drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Structure and mechanism of action of ADCs
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Zeng Y. Advances in mechanism and treatment strategy of cancer. Cell Mol Biol (Noisy-le-grand) 2018;64:1–3. doi: 10.14715/cmb/2018.64.6.1. - DOI - PubMed
    1. Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: combining targeting ability with cytotoxicity effectively. Cancer Med. 2021;10:4677–96. doi: 10.1002/cam4.4052. - DOI - PMC - PubMed
    1. Norsworthy KJ, Ko CW, Lee JE, Liu J, John CS, Przepiorka D, Farrell AT, Pazdur R. FDA approval Summary: Mylotarg for treatment of patients with relapsed or refractory CD33-Positive Acute Myeloid Leukemia. Oncologist. 2018;23:1103–8. doi: 10.1634/theoncologist.2017-0604. - DOI - PMC - PubMed
    1. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. doi: 10.1038/s41392-022-00947-7. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources